Bank of America Lowers Abbott Laboratories (NYSE:ABT) Price Target to $120.00

Abbott Laboratories (NYSE:ABT) had its price target cut by Bank of America from $150.00 to $120.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. Bank of America‘s price objective suggests a potential upside of 26.22% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Oppenheimer decreased their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup decreased their target price on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Piper Sandler reduced their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Finally, BTIG Research dropped their target price on Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $132.60.

Abbott Laboratories Trading Down 6.4%

Shares of ABT stock opened at $95.08 on Friday. The stock’s fifty day moving average is $108.17 and its two-hundred day moving average is $119.01. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm has a market capitalization of $165.59 billion, a P/E ratio of 25.56, a PEG ratio of 1.62 and a beta of 0.79. Abbott Laboratories has a fifty-two week low of $93.92 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the company earned $1.09 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter worth about $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 results narrowly beat expectations: adjusted EPS $1.15 vs. $1.14 consensus and revenue $11.16B (up 7.8% y/y), supported by cancer-diagnostics and medical-device strength. Abbott first-quarter results beat on cancer diagnostics, medical device strength
• Positive Sentiment: Exact Sciences acquisition expands Abbott into high-growth oncology diagnostics and is presented as strategic long-term growth even though it creates near-term EPS dilution. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
• Positive Sentiment: Broker support and insider activity: RBC Capital reaffirmed its buy rating and company insiders added shares, both signals of continued institutional/management confidence. RBC Capital Reaffirms Their Buy Rating on Abbott Laboratories (ABT) Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings
• Negative Sentiment: Guidance cut and dilution: Abbott lowered FY2026 adjusted EPS to $5.38–$5.58 (includes ~$0.20/share dilution from Exact Sciences) and Q2 EPS to $1.25–$1.31, below Street expectations — the guidance hit is the primary reason investors sold shares. Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
• Negative Sentiment: Margin pressure and weak Nutrition segment: management flagged margin compression and a prolonged slump in nutrition sales (plus a milder flu season that hurt consumer-test volumes), which weigh on near-term profit recovery. Abbott Stock Falls Despite Q1 Earnings & Revenue Beat Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
• Negative Sentiment: Market reaction: Despite the beat, investors focused on the weaker guide and merger-related costs, sending the stock lower (coverage pieces and commentaries explain the selloff). Why Abbott Laboratories Stock Tumbled on Thursday

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.